These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

863 related articles for article (PubMed ID: 9240729)

  • 1. Is skeletal responsiveness to thyroid hormone altered in primary osteoporosis or following estrogen replacement therapy?
    Langdahl BL; Loft AG; Møller N; Weeke J; Eriksen EF; Mosekilde L; Charles P
    J Bone Miner Res; 1997 Jan; 12(1):78-88. PubMed ID: 9240729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.
    Garnero P; Sornay-Rendu E; Chapuy MC; Delmas PD
    J Bone Miner Res; 1996 Mar; 11(3):337-49. PubMed ID: 8852944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skeletal responsiveness to thyroid hormone is not altered at menopause.
    Langdahl BL; Loft AG; Møller N; Weeke J; Eriksen EF; Mosekilde L; Charles P
    Bone; 1996 Nov; 19(5):557-64. PubMed ID: 8922657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis.
    Seibel MJ; Cosman F; Shen V; Gordon S; Dempster DW; Ratcliffe A; Lindsay R
    J Bone Miner Res; 1993 Jul; 8(7):881-9. PubMed ID: 8352070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral 1,25-dihydroxyvitamin D administration in osteoporotic women: effects of estrogen therapy.
    Cosman F; Nieves J; Shen V; Lindsay R
    J Bone Miner Res; 1995 Apr; 10(4):594-600. PubMed ID: 7610930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Normal osteoclastic and osteoblastic responses to exogenous growth hormone in patients with postmenopausal spinal osteoporosis.
    Kassem M; Brixen K; Blum WF; Mosekilde L; Eriksen EF
    J Bone Miner Res; 1994 Sep; 9(9):1365-70. PubMed ID: 7817819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women.
    Cosman F; Nieves J; Woelfert L; Shen V; Lindsay R
    J Bone Miner Res; 1998 Jun; 13(6):1051-5. PubMed ID: 9626638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Body mass index (BMI) and parameters of bone formation and resorption in postmenopausal women.
    Papakitsou EF; Margioris AN; Dretakis KE; Trovas G; Zoras U; Lyritis G; Dretakis EK; Stergiopoulos K
    Maturitas; 2004 Mar; 47(3):185-93. PubMed ID: 15036488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical markers as predictors of rates of bone loss after menopause.
    Rogers A; Hannon RA; Eastell R
    J Bone Miner Res; 2000 Jul; 15(7):1398-404. PubMed ID: 10893690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
    Chen P; Satterwhite JH; Licata AA; Lewiecki EM; Sipos AA; Misurski DM; Wagman RB
    J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term treatment with growth hormone stimulates osteoblastic and osteoclastic activity in osteopenic postmenopausal women: a dose response study.
    Brixen K; Kassem M; Nielsen HK; Loft AG; Flyvbjerg A; Mosekilde L
    J Bone Miner Res; 1995 Dec; 10(12):1865-74. PubMed ID: 8619366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skeletal involvement in female acromegalic subjects: the effects of growth hormone excess in amenorrheal and menstruating patients.
    Scillitani A; Chiodini I; Carnevale V; Giannatempo GM; Frusciante V; Villella M; Pileri M; Guglielmi G; Di Giorgio A; Modoni S; Fusilli S; Di Cerbo A; Liuzzi A
    J Bone Miner Res; 1997 Oct; 12(10):1729-36. PubMed ID: 9333135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.
    Alvarez L; Guañabens N; Peris P; Monegal A; Bedini JL; Deulofeu R; Martinez de Osaba MJ; Muñoz-Gomez J; Rivera-Fillat F; Ballesta AM
    J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlations of serum prolidase activity between bone turnover markers and mineral density in postmenopausal osteoporosis.
    Verit FF; Geyikli I; Yazgan P; Celik A
    Arch Gynecol Obstet; 2006 Jun; 274(3):133-7. PubMed ID: 16532321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of chronic liver disease on bone mineral density and bone metabolism markers in postmenopausal women.
    Uretmen S; Gol M; Cimrin D; Irmak E
    Eur J Obstet Gynecol Reprod Biol; 2005 Nov; 123(1):67-71. PubMed ID: 16051419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability.
    Hannon R; Blumsohn A; Naylor K; Eastell R
    J Bone Miner Res; 1998 Jul; 13(7):1124-33. PubMed ID: 9661076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring alendronate therapy for osteoporosis.
    Braga de Castro Machado A; Hannon R; Eastell R
    J Bone Miner Res; 1999 Apr; 14(4):602-8. PubMed ID: 10234582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term intravenous bisphosphonates in prevention of postmenopausal bone loss.
    Heikkinen JE; Selander KS; Laitinen K; Arnala I; Väänänen HK
    J Bone Miner Res; 1997 Jan; 12(1):103-10. PubMed ID: 9240732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis.
    Hodsman AB; Fraher LJ; Ostbye T; Adachi JD; Steer BM
    J Clin Invest; 1993 Mar; 91(3):1138-48. PubMed ID: 8450043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.